State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses

Chimeric antigen receptor T cell (CAR-T) therapy has shown unprecedented response rates in patients with relapsed/refractory (R/R) hematologic malignancies. Although CAR-T therapy gives hope to heavily pretreated patients, the rapid commercialization and cumulative immunosuppression of this therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Meir, Juliet, Abid, Muhammad Abbas, Abid, Muhammad Bilal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473073/
https://www.ncbi.nlm.nih.gov/pubmed/34587552
http://dx.doi.org/10.1016/j.jtct.2021.09.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473073/
https://www.ncbi.nlm.nih.gov/pubmed/34587552
http://dx.doi.org/10.1016/j.jtct.2021.09.016

Ejemplares similares